Target intelligence / Profile preview

Ferritin heavy chain 1 (FTH1)

Target
FTH1
Molecular classification
Enzyme (ferroxidase), Iron-binding protein, Storage protein, Other (intracellular iron homeostasis)
01

Overview

Ferritin heavy chain 1 is a subunit of the ferritin complex, the primary intracellular iron storage protein in humans and other species. It possesses ferroxidase activity, enabling the oxidation of Fe²⁺ (ferrous) to Fe³⁺ (ferric) iron, which is subsequently stored inside the ferritin shell in a non-toxic and bioavailable form. The FTH1 gene is located on chromosome 11, and mutations can cause diseases such as Hemochromatosis type 5 and are implicated in neurodegenerative disorders. FTH1 is essential for cellular and organismal iron homeostasis, protection from iron-driven oxidative stress, regulation of ferroptosis (an iron-dependent cell death pathway), and has roles in immune response and cell proliferation. Clinically, serum ferritin (total, not just heavy chain) is used as a biomarker for iron stores, but levels can be elevated in inflammation and malignancy independent of iron load.

Other names
Ferritin heavy chainFerritin H subunitFTHFTHL6Cell proliferation-inducing gene 15 protein
02

Mechanism of action

Iron chelators: Reduce ferritin iron load, indirectly affect FTH1 function. Small molecules (investigational): May target ferritin to induce degradation or modulate iron release for anti-cancer or neuroprotective effects

03

Biological functions

Iron storage in a soluble and non-toxic stateMaintenance of intracellular iron homeostasisFerroxidase activity (catalyzes Fe2+ to Fe3+ conversion)Negative regulation of ferroptosisAntioxidant activityRegulation of cell proliferationDelivery of iron to cells
04

Disease associations

Neurodegenerative diseaseHemochromatosis (type 5)Cancer (as an iron/survival/metabolic marker)Other diseases linked to iron metabolism or overload
05

Safety considerations

Excess ferritin or iron overload is associated with toxicity (hemochromatosis, organ damage)Deficiency leads to iron-depletion syndromes (anemia, neurodegeneration)Non-specificity: Ferritin is an acute-phase reactant and may be elevated in inflammation, cancer, and infection regardless of iron status
06

Interacting drugs

Directly interacting drugs are not widely established in clinical use; iron chelators (such as deferoxamine) and investigational agents modulating ferritin or iron levels may have indirect or experimental relevance
07

Biomarkers

Serum and tissue ferritin levels as a marker of iron storage, overload, or inflammationUsed in diagnosis/monitoring of hemochromatosis, anemia, infections, inflammatory diseases, and some cancers

Beyond the preview

Go deeper on Ferritin heavy chain 1 (FTH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ferritin heavy chain 1 (FTH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call